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Relative stabilityThe construct of alexithymia as a vulnerability factor for substance use disorders (SUD) is under debate, because
of conﬂicting research results regarding alexithymia as a state or trait phenomenon. The absolute and relative
stability of alexithymia were evaluated in a pre-post design as part of a randomised controlled trial, controlling
for several co-variates. Assessments were done with the Toronto Alexithymia Scale (TAS-20) and the Addiction
Severity Index (EuropASI) at baseline and follow-up of a 3-month trial of inpatient Cognitive Behavioural Ther-
apy (CBT)with orwithout a SharedDecisionMaking intervention for 187 SUDpatients. Paired sample t-tests and
analyses of variancewere performed to assess absolute stability, intraclass correlation coefﬁcients were calculat-
ed for relative stability andmultivariate linear regressionmodels were used to evaluate the relation between co-
variates and change in alexithymia. Mean level reduction of total TAS-20 and two subfactors demonstrated no
absolute stability, but change in alexithymia differed for patients with low, moderate and high alexithymia
scores. Relative stability of alexithymia was moderate to high for the total population, but differed according
to low, moderate and high alexithymia scores. The EuropASI “psychiatry” domain, covering anxiety and depres-
sion, was related to alexithymia, but CBT-related variables were not. In conclusion, alexithymia is partly a state-
dependent phenomenon, but not a stable personality trait in this SUD population.
© 2012 Elsevier Ireland Ltd. Open access under the Elsevier OA license.1. Introduction
Alexithymia refers to the difﬁculty in identifying and describing
feelings, the inability to discriminate between feelings and physical
sensations, having a limited fantasy life and the inclination to an exter-
nally orientedway of thinking (Sifneos, 1973). The Toronto Alexithymia
Scale (TAS-20) is worldwide the most frequently used assessment in-
strument for alexithymia and includes three factors: (1) difﬁculty in
identifying feelings (DIF), (2) difﬁculty in describing feelings (DDF)
and (3) externally oriented thinking (EOT) (Bagby et al., 1994).
A Dutch study (van Rossum et al., 2004) reported 54% of alcohol use
disorder (AUD) patients to be alexithymic with a mean score of 56 on
the TAS-20, a ﬁnding that is in accord with research on alcohol-related
disorders in other studies (Thorberg et al., 2009). In other substance
use disorder (SUD) populations alexithymia rates up to 67% have
been found (Taylor et al., 1997; El Rasheed, 2001; Dorard et al.,
2008).
Based on a reduction in alexithymia scores after detoxiﬁcation in a
homogeneous AUD population, it is suggested that alexithymia is aP.O. Box 154, 7400ADDeventer,
115.
 the Elsevier OA license.state-related phenomenon resulting from anxiety and depression
(Haviland et al., 1988). In a comparable study with a heterogeneous
SUD population (Pinard et al., 1996), however, no change in alexithy-
mia scores was found and alexithymia appeared to be a stable trait. In
a recent study in homogeneous AUD patients, the absolute and relative
stability of alexithymia was evaluated during alcohol withdrawal; an
absolute reduction (i.e., no absolute stability) of alexithymia scores
was found (de Timary et al., 2008). The observed high relative stability
over three time points, as well as the restricted inﬂuence of anxiety and
depression, supported the view that alexithymia is a stable personality
trait rather than a state-dependent phenomenon. The absolute decrease
in alexithymia mean level score was in this study completely explained
by a decrease of the DIF-factor.
In the literature there is an extensive debate on the state versus
trait concept of alexithymia that focuses on the concept of absolute
and relative stability of alexithymia as a personality characteristic.
Previous research showed that stability status may change according
to the population that is studied (Pinard et al., 1996; Honkalampi et
al., 2001; Luminet et al., 2001; Rufer et al., 2004; Saarijarvi et al.,
2006; Luminet et al., 2007; Stingl et al., 2008; de Timary et al., 2008).
Absolute stability refers to the extent to which average personality
scores or trait levels of a population change. It is assessed by mean-
level differences over time. These indicate if and in which direction
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review or meta-analysis on the stability of alexithymia as a personality
trait does not exist, but a meta-analysis of longitudinal studies of per-
sonality traits, according to the Five-Factor Model, provided evidence
for continued plasticity beyond age 30 (Roberts et al., 2006).
Relative or rank-order stability indicates the extent to which the
relative differences among individuals remain the same over time
and is assessed by test–retest correlations (Caspi et al., 2005). From
a meta-analysis of the rank–order stability of personality, also based
on the Five-Factor Model, test–retest correlations were moderate in
magnitude over time (Roberts and DelVecchio, 2000). There was an
increase with age and a decrease with increasing intervals between
the observations. Rank–order stability peaked sometime after age
50, at a level below unity, thus also indicating that personality traits
continue to change throughout adulthood. Both meta-analyses
(Roberts and DelVecchio, 2000; Roberts et al., 2006) demonstrate
that personality trait development is not just a phenomenon of child-
hood or adolescence but continues during adulthood.
Alexithymia has been associated with negative treatment out-
comes in different SUD populations (Loas et al., 1997; Ziolkowski et
al., 1995; Cleland et al., 2005), which could be a rationale for addres-
sing alexithymia in treating SUD patients. However, only as a stable
personality trait can alexithymia be an autonomous vulnerability fac-
tor for SUD, as has also been suggested by de Timary et al. (2008). As a
state phenomenon, alexithymia is not an autonomous vulnerability
factor because, as has been shown, it is highly related to anxiety
and depression in different populations (Haviland et al., 1988;
Honkalampi et al., 2000). Anxiety and mood disorders both have a
high co-morbidity with SUD and are predictors themselves for SUD
(Compton et al., 2007; Grant et al., 2009).
The stability of alexithymia during or after treatment was investi-
gated in several studies with conﬂicting results with regard to abso-
lute stability. Most studies, however, supported the relative stability
of alexithymia (Porcelli et al., 2003; Rufer et al., 2004; Micolajczak
and Luminet, 2006; Rufer et al., 2006; Saarijarvi et al., 2006;
Luminet et al., 2007; Spek et al., 2008; Stingl et al., 2008). Depression
was as a co-variable related to change in mean level alexithymia
scores, especially in the DIF factor, but there was little or no relation
to the EOT factor (Luminet et al., 2001).
There has been little research into the effects of psychotherapy on
alexithymia and the available results are ambiguous. Some studies
reported no change (Iancu et al., 2006), whereas others found a de-
crease in alexithymia during treatment (Lumley et al., 2007). In all
these studies, the interventions were not speciﬁcally aimed at reducing
alexithymia; thus, the changes seen could have reﬂected a reduction in
associated symptoms such as depression, anxiety or psychological
stress (Stingl et al., 2008).
Only a few reported studies (Beresnevaite, 2000; Gay et al., 2008)
were speciﬁcally aimed at reducing alexithymic characteristics. In one
of the studies group psychotherapy was associated with a decrease in
mean levels of alexithymia with a resulting favourable inﬂuence on
the clinical course of patients with coronary heart disease. But the rel-
ative stability was still high 2 years after therapy (Beresnevaite,
2000).
Evaluations of alexithymia in homogeneous and heterogeneous
SUD (Keller et al., 1995; Rosenblum et al., 2005) did not show a spe-
ciﬁc impact of various therapies on alexithymia scores. However, in
one study (Rosenblum et al., 2005) alexithymic SUD patients proﬁted
more from a cognitive behavioural treatment (CBT) than from a mo-
tivational enhancement intervention.
Given the conﬂicting results concerning the stability of alexithy-
mia in detoxifying or recently detoxiﬁed homogeneous AUD and het-
erogeneous SUD populations (Haviland et al., 1988; Pinard et al.,
1996; de Timary et al., 2008) and the assumption that alexithymia
only as a stable personality trait is a vulnerability factor for SUD, we
were interested in evaluating the stability of alexithymia in adetoxiﬁed heterogeneous SUD population after an inpatient treat-
ment intervention. If alexithymia were not a stable personality trait
and therefore not a vulnerability trait for SUD, there would be no
need to assess and address alexithymia in SUD patients. Because the
therapy was not speciﬁcally aimed at reducing alexithymic characteris-
tics, we hypothesised that a) a mean level reduction of alexithymia and
factor scores relates to a reduction in anxiety and/or depression; b) no
differences in change of mean level alexithymia scores will be observed
between “low”, “moderate” and “high” alexithymic patients, when con-
trolled for anxiety and depression; c) there is a moderate to high rel-
ative stability of alexithymia; and d) there is no difference in relative
stability between “low”, “moderate” and “high” alexithymic patients.
In addition if it is shown that variance in follow-up alexithymia could
be better predicted by baseline alexithymia than “state” conditions,
like anxiety and depression, this will support the argument for the rel-
ative stability of alexithymia.
2. Methods
2.1. Subjects
Subjects were inpatients recruited from three addiction treatment centres in the
East and South part of The Netherlands: Vincent van Gogh Institute, department Addic-
tion Treatment, Novadic-Kentron and Tactus Addiction Treatment. The main study was
a randomised controlled trial of Shared Decision Making (SDM) that was carried out
from January 2005 to December 2006.
All 261 inpatients hospitalised during the study period with different forms of SUD
were assessed for eligibility. Due to exclusion criteria (being under the age of 18, insuf-
ﬁcient knowledge of the Dutch language, severe psychiatric co-morbidity precluding
taking part in the study or no signed informed consent), refusal or early withdrawal,
a total of 227 patients were randomised. Because seven patients later refused to partici-
pate and eight patients could not start because of an untimely stop at one study location,
107 patients started the SDM intervention (SDM-CBT) and 105 patients started in the con-
trol group: decisionmaking as usual, i.e. treatment as usual (TAU-CBT). However, TAS-20
baseline datawere available only for 187 patients and complete TAS-20 follow-updata for
140 and incomplete data (i.e. not all TAS-20 dimensions) for 151 patients. All patients had
been diagnosed according toDSM-IV-TR as having one ormore substance related disorders.
At follow-up evaluation, patients received a voucher for EUR 20. The studywas approved by
the Dutch Ethical Assessment Committee for Experimental Investigations on People (No.
4.108).
2.2. Interventions
SDM-CBT was an add-on intervention on a standardised 3-month inpatient course
of CBT with elements of motivational interviewing (MI), relapse prevention, social
skills training and both individual and group components. SDM-CBT was a structured
approach to reach a combined treatment over ﬁve sessions and was also partly based
on MI techniques (Miller, 1996). The TAU-CBT group received the same standardised
3-month inpatient CBT without the SDM intervention. In The Netherlands, MI is well
known and used to motivate SUD patients to participate in treatment. In the SDM-
CBT group, MI was applied by protocol to evaluate indicated treatment goals. In the
TAU-CBT group MI was also used but in an unstructured way and all participating cen-
tres used similar, unstructured, procedures to reach treatment agreement with pa-
tients. For a detailed explanation of the interventions, see Joosten et al. (2009).
For the alexithymia study we pooled the two groups (SDM-CBT and TAU-CBT) and
controlled for intervention in the analyses.
2.3. Instruments
Alexithymia was assessed at baseline and at 3-month follow-up after a 3-month
inpatient treatment using the Dutch version of the TAS-20 comprising three dimen-
sions: (1) difﬁculty in identifying feelings (DIF), (2) difﬁculty in describing feelings
(DDF) and (3) externally oriented thinking (EOT). Each item consists of a ﬁve-point
Likert scale ranging from “completely disagree” to “completely agree”. The TAS-20
can be analysed in its entirety or the three components can be analysed separately
(Kooiman et al., 2002, Taylor et al., 1997). The TAS-20 total scores were categorised
according to the empirically derived cut-off points suggested by Taylor et al. (1997):
scores of 61 and above represent a “high” degree of alexithymia; scores of 51 or
below indicate a “low” degree and from 52 to 60 a “moderate” degree of alexithymia.
The Dutch total TAS-20 showed a good internal consistency in student and outpatient
psychiatric populations with Cronbach's α varying between 0.79 and 0.82. The internal
consistency for the DIF factor was good, for the DDF factor moderate to good, and for
the EOT factor unsatisfactory (Cronbach's α: 0.52–0.66) (Kooiman et al., 2002).
The substance disorder was assessed and typiﬁed by using the Composite Interna-
tional Diagnostic Interview, Substance Abuse Module (CIDI-SAM) at baseline
(Compton et al., 1996). The CIDI-SAM is an expanded and more detailed version of
the substance use sections of the CIDI. The interview questions address the diagnostic
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Organization, 1992) for psychoactive substance use disorders.
Severity of substance use was established on the basis of the European Addiction
Severity Index (EuropASI) at baseline and at 3-month follow-up, that is, 3 months
after ﬁnishing the 3-month inpatient treatment (McLellan et al., 1980; Hendriks et
al., 1989). The EuropASI is a clinical research interview designed to assess problem se-
verity in the following seven domains of functioning: physical health, employment, al-
cohol and/or drug use, legal, family/social and psychiatric. The Dutch version of
EuropASI used in the present study also includes gambling. Eight severity scores that
could range from 0 (no problem) to 9 (extremely serious problem) were derived
from this interview. The psychiatric severity rating of the Dutch ASI is moderately cor-
related with the Beck Depression Inventory (BDI) (Beck et al., 1961) and the Symptom
Check List-90 (SCL-90) (Derogatis et al. 1973) mean score. Subscales of the SCL-90 also
show moderate correlations with the psychiatric severity rating, with coefﬁcients
ranging from 0.48 for “depression” to 0.52 for “anxiety” (Hendriks et al., 1989).
Independent interviewers, not related to the treatment of patients, with a bachelor's
or master's degree in psychology carried out the 3-month follow-up measurements.
2.4. Statistical analysis
The absolute stability of the TAS-20, factor scores and EuropASI severity domains
between baseline and 3-month follow-up were tested with paired t-tests.
Cohen's d=(μ1–μ2)/σ1 was calculated to determine the effect sizes for signiﬁcant
variables. Cohen deﬁnes d of 0.2, 0.5 and 0.8 as small, medium and large effects, respec-
tively (Cohen, 1988). The differences in absolute stability between “low”, “moderate”
and “high” alexithymia scores were also tested by comparing the difference scores
(subtracting baseline from follow-up alexithymia scores) with analysis of variance.
Intraclass correlations were used to assess the relative stability of TAS-20 and factor
scores between baseline and follow-up.
Multivariate linear regression models were performed with total alexithymia and
factor scores at follow-up as the dependent variables. The predictor variables, partly
based on previous research (Haviland et al., 1994, Rosenblum et al., 2005, Mattila et
al., 2006, Joosten et al., 2009), were the EuropASI baseline and follow-up scores, age,
gender, time in treatment, type of intervention (SDM-CBT or TAU-CBT) and baseline
total alexithymia or factor scores. Effect modiﬁcation was formally assessed by interac-
tion terms between intervention type and baseline total alexithymia or factor scores.
Variables with a pb0.15 in univariate analyses (correlations between predictors and
the different dependent variables) were entered in a full multivariatemodel. Subsequent-
ly, non-signiﬁcant variables were removed, one by one, until R-squared changed bymore
than 10%.
To assess to what extent changes in alexithymia can be accounted for by therapy-
related variables, multivariate linear regression models were performed with TAS-20
and factor “change scores” (baseline minus follow-up scores) as the dependent vari-
ables and the EuropASI “change scores”, age, gender, time in treatment, type of inter-
vention (SDM-CBT versus TAU-CBT) and degree of baseline alexithymia as the
predictor variables. Effect modiﬁcation was formally assessed by interaction terms be-
tween intervention type anddegree of baseline total alexithymia or factor scores. Variables
with a pb0.15 in univariate analyses (correlations betweenpredictors and thedifferent de-
pendent variables) were entered in a full multivariate model. Subsequently, non-
signiﬁcant variables were removed, one by one, until R-squared changed by more than
10%.
All statistical tests were 2-sided, with a p-value≤0.05 considered to indicate statis-
tical signiﬁcance and performed using SPSS for Windows (release 16.0).
3. Results
3.1. Baseline characteristics
TAS-20 baseline data were available for 187 patients, with no spe-
ciﬁc cause for this loss of data. No differences in baseline characteris-
tics were found between these 187 patients and the (212–187) 25
other patients of the SDM-CBT and TAU-CBT groups (data not
shown). Sixty-nine patients (36.9%) scored as “high” alexithymic,
29.4% (n=56) as “moderate” and 33.2% (n=62) as “low” alexithy-
mic. The mean baseline TAS-20 score for all patients was 55.9
(S.D.=11.1). One hundred forty (75%) were male patients. Mean
age was 40.7 (S.D.=10.9) and mean years of education 11.4Table 1
Follow-up data for abstinence, time in treatment and drop-out (n=187).
Characteristics Low alexithymic (TAS-20b52) Moderate alexithy
Abstinence (%) 45.7% 50.0%
Time in treatment, mean (S.D.) 105.1 (48.6) 106.2 (53.0)
Drop-out (%) 56.5 58.9(S.D.=3.0). Forty-four percent had never been married, 39% were di-
vorced or widowed and 17% were still married. Forty-four percent
had no work and 94% were born in The Netherlands. In 54% alcohol
was the substance of preference, cocaine or other stimulants in 11%,
cannabis in 4%, polydrug use in 29% and other substances in 2%.
There were no differences between men and women in substance
use preference. To give insight into the most prominent differences
of the degree of alexithymia on baseline characteristics, we compared
the high and low alexithymia groups and left the moderate group out.
“High” alexithymic patients did not differ from “low” alexithymic pa-
tients in gender, age, country of birth, relationship, type of substance
dependence, or substance preference, but fewer were employed
[χ²(1)=3.9, p=0.05] and “high” alexithymics had fewer years of edu-
cation [t(129)=2.0, p=0.05]. On the EuropASI scores, they differed
only on the “work, education and income” domain [M “high” alex-
ithymics=4.0 (S.D.=1.8); M “low” alexithymics=3.3 (S.D.=1.9);
t(129)=2.1, p=0.04] and the “psychiatry” domain [M “high” alex-
ithymics=6.8 (S.D.=1.2); M “low”-alexithymics=5.1 (S.D.=2.4);
t(129)=5.23, pb0.001]. Alexithymia measured as a continuous var-
iable was also related to years of education (r=−0.19, p=0.01) and
the EuropASI “psychiatry” section (r=0.31, pb0.001), but not to the
“work, education and income” section (r=0.12, p=0.11).
No differences were found in percentages between high, moderate
and low alexithymic patients regarding type of intervention [χ²(2)=
0.0, p=0.99]. In the SDM-group 36.7% were high, 30.0% moderate
and 33.3% low alexithymic. In the TAU-group 37.1% were high,
29.9% moderate and 30.0% low alexithymic.
Baseline characteristics showed no signiﬁcant differences between
completers and drop-outs for EuropASI, TAS-20, and factor scores,
age, gender and type of intervention (data not shown). No differences
were found in total TAS-20 scores between the four main addiction
types in our sample, based on the primary addiction of the patients,
i.e. alcohol, polydrug, stimulants and other substances (data not
shown).
3.2. Follow-up data
Because of differences in missing values between the factor scores
of alexithymia, complete TAS-20 scores for baseline and follow-up
were available for 140 patients, DIF scores for 148, DDF scores for
151 and EOT scores for 143 patients. Abstinence, drop-out and time
in treatment were not different for baseline “low”, “moderate” and
“high” alexithymic patients (Table 1). To be sure that we could pool
the four main addiction types together, we performed an analysis of
variance (ANOVA) on the difference scores for the total TAS-20 be-
tween baseline and follow-up and found no signiﬁcant differences
(data not shown). As part of the drop-out analyses, we compared
the 140 patients with complete TAS-20 follow-up scores with the
72 of the 212 baseline participants without these scores. Both groups
differed on type of substance preference[χ²(3)=8.8, p=0.03] with
55.8% of the TAS-20 follow-up group showing a preference for alco-
hol, 6.5% for stimulants, 31.9% for polydrug use, and 5.8% for other
substances. For the group without TAS-20 follow-up scores, the per-
centages were, respectively, 47.9%, 18.3%, 23.9% and 9.9%. Next, in
the SDM-CBT group, 57.9% had TAS-20 follow-up scores and in the
TAU-CBT group 74.3% [χ²(1)=6.3, p=0.01]. Time in treatment was
also different. The mean of the group with TAS-20 follow-up scores
was 115.1 days (S.D.=56.2) and for the group without, the meanmic (51bTAS-20b61) High alexithymic (TAS-20>60) χ² F p
52.0% 0.40 0.82
116.0 (58.9) 0.81 0.45
49.3 1.30 0.52
Table 2
TAS-20 total and factor scores and EuropASI scores from baseline to follow-up: paired
sample t-tests.
Severity-scores
Mean (S.D.)
Baseline Follow-up T p d (Cohen)
TAS-20 (n=140) 55.9 (11.1) 53.8 (11.8) 2.3 0.02 0.19
DIF (n=148) 19.1 (6.0) 18.0 (6.5) 2.1 0.04 0.18
DDF (n=151) 16.3 (4.3) 15.0 (4.0) 3.8 b0.001 0.31
EOT (n=143) 20.4 (4.1) 20.6 (3.9) −0.4 0.67 −0.04
EuropASI scores (n=152)
Physical health 2.6 (2.1) 1.9 (2.0) 5.0 b0.001 0.33
Work, education
and income
3.5 (1.8) 2.7 (2.0) 5.1 b0.001 0.39
Alcohol 5.3 (2.5) 3.4 (2.4) 9.6 b0.001 0.72
Drugs 3.2 (3.2) 2.0 (2.6) 8.0 b0.001 0.34
Legal 1.5 (1.8) 0.4 (1.1) 8.5 b0.001 0.58
Family/social relations 4.3 (1.5) 2.4 (2.1) 9.5 b0.001 1.27
Psychiatric 5.7 (2.0) 3.6 (2.4) 9.8 b0.001 1.10
Gambling 0.3 (1.0) 0.1 (0.6) 3.2 0.001 0.20
Note: TAS-20 = “Toronto Alexithymia Scale”; DIF = “Difﬁculty Identifying Feelings”;
DDF = “Difﬁculty Describing Feelings”; EOT = “Externally Oriented Thinking”.
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ences were found (data not shown).
3.3. Absolute stability
The paired sample t-tests showed signiﬁcant reductions in total
TAS-20, DIF and DDF scores from baseline to follow-up with small ef-
fect sizes. For the EuropASI domains the reductions at follow-up were
all signiﬁcant and effect sizes varied from small (d=0.20: gambling)
to large (d=1.27: family/social relations) (Table 2).
The mean change scores (baseline minus follow-up) for the TAS-20
and the different factors between “low”, “moderate” and “high”
alexithymic patients were highly signiﬁcant (Table 3). Post-hoc
analyses showed that the changes for the “high” alexithymics differed
from the “low” alexithymics and, except for the DDF factor, also from
the “moderate” alexithymics. “Low” alexithymics differed on the total
TAS-20 and the DDF factor from the “moderate” alexithymics. The
total and factor TAS-20 scores for “low” alexithymic patients were
larger at follow-up compared with baseline, while the scores for
“moderate” and “high” alexithymic patients were lower (the reduction
was greatest in “high” alexithymics). ANOVA on the mean change
scores of the EuropASI psychiatry domain, measuring also depression
and anxiety, for baseline “low” (M=2.0, S.D.=2.8), “moderate”
(M=1.6, S.D.=2.6) and “high” (M=2.7, S.D.=2.5) alexithymic
patients indicated no signiﬁcant differences [F(2,130)=2.12, p=0.12].
3.4. Relative stability
The intraclass correlation (ICC) for the total TAS-20 between base-
line and follow-up was 0.52, for DIF 0.45, DDF 0.44, and EOT 0.42 (all
pb0.001). This means that effect sizes for relative stability were all on
a moderate to high level. ICCs for patients with a baseline “low”,
“moderate” or “high” alexithymic score differed considerably, espe-
cially on the total TAS-20. Baseline “moderate” alexithymic patientsTable 3
Mean difference score for TAS-20 and factor scores (baseline – follow-up) for low (TAS-20b
line: ANOVA.
Low alexithymia Mean (S.D.) (n) Moderate alexithymia Mean (S.D
Total TAS-20 −3.8 (11.2) (52) 1.5 (9.8) (43)
DIF −1.9 (6.1) (46) 0.8 (6.2) (45)
DDF −0.9 (4.3) (47) 1.7 (4.2) (46)
EOT −1.2 (4.8) (46) −0.8 (4.0) (44)
Note: TAS-20 = “Toronto Alexithymia Scale”; DIF = “Difﬁculty Identifying Feelings”; DDFhad non-signiﬁcantly low ICCs (except for EOT), and “low” and
“high” alexithymic patients had nearly all signiﬁcantly low to moder-
ate ICCs. Only the EOT factor demonstrated signiﬁcant ICCs for all pa-
tients (Table 4).
In predicting TAS-20 score at follow-up, the follow-up EuropASI
factor “psychiatry” (β=0.22) contributed a small part compared
with the TAS-20 at baseline (β=0.50) (Table 5). Regarding the pre-
diction of the DIF factor at follow-up, baseline DIF contributed just a
little more (β=0.44) to the variance than “psychiatry” at follow-up
(β=0.29), age (β=0.21) and the baseline EuropASI “alcohol” do-
main (β=−0.16). In predicting the DDF factor at follow-up, the
“drugs” domain at baseline contributed a smaller part to the variance
(β=0.20) than baseline DDF (β=0.47). The “legal” domain at
follow-up contributed to the variance (β=0.19) of the EOT factor
at follow-up, but less than the baseline EOT factor (β=0.41)
(Table 5).
Performing regression models with total TAS-20 and factor
“change scores” as the dependent variables, gender, type of interven-
tion, time in treatment and all EuropASI “change scores” except the
“psychiatry” and “drugs” domains did not have any predictive value.
EuropASI “psychiatry” change score contributed small parts (β: 0.13
to 0.21) to the variance of the TAS-20 and factor “change scores”
(Table 6). Baseline alexithymia as a categorical variable explained
larger parts of the variances (β: 0.28 to 0.48). Age was negatively re-
lated to the change in the DIF factor and contributed minimally to the
variance (β=−0.15). The “change score” of the EuropASI “drugs” do-
main was inversely related to the “change score” of the DDF factor
and explained a small part (β=−0.17) of the variance. For both
the regression models no effect modiﬁcation by treatment assign-
ment was present.
4. Discussion
The baseline alexithymia mean score of 55.7 on the TAS-20 and the
prevalence of “high” alexithymic patients of 37% is comparable to other
reported homogeneous and heterogeneous SUD studies (de Timary et
al., 2008; Dorard et al., 2008; Taylor et al., 1997). A higher score on the
EuropASI “psychiatry” domain for alexithymic patients is in line with
the higher scores on depression and anxiety in recently detoxiﬁed homo-
geneous AUD patients (Haviland et al., 1988; de Timary et al., 2008).
However, the EuropASI is not an optimal instrument for measuring de-
pression and anxiety. More unemployment and less education match a
larger score for “high” alexithymic patients on theEuropASI “work, educa-
tion and income” domain, conﬁrming previous epidemiological studies
(Saarijarvi et al., 1993; Mattila et al., 2006).
Unlike the study of Pinard et al. (1996), but in accord with de
Timary et al. (2008), we did not ﬁnd absolute stability in total TAS-
20 and factor scores. Pinard et al. (1996) found an insigniﬁcant in-
crease in total TAS-20 and factor scores after 4–6 weeks of abstinence,
but the study population was very small (n=21). In the study of de
Timary et al., the EOT factor, with no gender difference, and the DDF
factor, only for men, showed absolute stability. The reduction
reported by de Timary et al. (2008) in 14–18 days (difference
score=4.1, Cohen's d=0.38) for the total TAS-20 was larger than
the reduction we found (difference score=2.1, Cohen's d=0.19) in52), moderate (51bTAS-20b61) and high (TAS-20>60) alexithymic patients at base-
.) (n) High alexithymia F mean (S.D.) (n) p Post-hoc (Tukey)
7.9 (9.0) (52) 16.74 b0.001 3>2>1
3.8 (6.0) (53) 10.79 b0.001 3>1,2
2.6 (3.4) (53) 10.20 b0.001 3,2>1
1.5 (3.8) (52) 5.91 0.003 3>1,2
= “Difﬁculty Describing Feelings”; EOT = “Externally Oriented Thinking”.
Table 4
Intra Class Correlations (ICCs) for TAS-20 and factors between baseline and follow-up for low, moderate and high baseline alexithymic patients.
ICC Low alexithymia (p) (n) Moderate alexithymia (p) (n) High alexithymia (p) (n)
Total TAS-20 0.30 (p=0.02) (n=45) −0.06 (p=0.67) (n=43) 0.20 (p=0.08) (n=52)
DIF 0.26 (p=0.04) (n=46) 0.15 (p=0.17 (n=45) 0.22 (p=0.05) (n=53)
DDF 0.33 (p=0.01) (n=47) 0.09 (p=0.26) (n=46) 0.28 (p=0.02) (n=53)
EOT 0.37 (p=0.005) (n=46) 0.33 (p=0.01) (n=44) 0.23 (p=0.05) (n=52)
Note: TAS-20 = Toronto Alexithymia Scale”; DIF = “Difﬁculty Identifying Feelings”; DDF = “Difﬁculty Describing Feelings”; EOT = “Externally Oriented Thinking”.
Table 6
127H. de Haan et al. / Psychiatry Research 198 (2012) 123–129about half a year. A larger decrease in depression and anxiety during
the detoxiﬁcation process could be responsible for this difference.
However, the effect sizes (T1–T3) for the reductions in BDI scores
(d=0.89) and for STAI scores (State-Trait Anxiety Inventory)
(d=0.95) in the de Timary et al. (2008) study were smaller than
our effect size for the reduction in the EuropASI “psychiatry” domain
(d=1.10).
Absolute changes in total TAS-20 scores vary for different
populations and different interventions, but also regarding the differ-
ent TAS-20 factors. We found mean level stability for the EOT factor
and mean level changes for the total TAS and DIF and DDF scores,
whereas others found mean level stability for DIF and EOT factors
(Rufer et al., 2004), for DDF (only for men) and EOT factors (de
Timary et al., 2008) or only for the DDF factor (Luminet et al., 2007).
However, our data demonstrated another prominent difference in
mean level stability for the total TAS-20 and the factor scores between
“low”, “moderate” and “high” alexithymic patients. The most obvious
change was a reduction for all TAS scores in the “high” alexithymia
group. In the “low” alexithymia group all the TAS scores increased.
The “moderate” group showed a more ambivalent outcome with a re-
duction for the total TAS, DIF and DDF factors and an increase for the
EOT factor. These results could not be explained by a related change in
anxiety and/or depression, as measured by the EuropASI “psychiatry”
domain. This phenomenon looks like a “regression toward the mean”
and is to our knowledge not described in previous research on stability
in alexithymia. Another study (Honkalampi et al., 2001) found, despite
an absolute stability of TAS scores, a shift from categories of alexithymia
at follow-up, but this could be explained by a related change of depres-
sion scores. Besides, the magnitude of change between the categories
was difﬁcult to interpret because of the borderline problems near theTable 5
Multivariate linear regression analysis predicting TAS-20 total and factor scores at
follow-up from EuropASI severity scores, gender, age, time in treatment, intervention
type and TAS-20 at baseline. Non-signiﬁcant variables were removed until R-squared
changed by more than 10%.
Factors β p R² F change p
Total TAS-20 (n=140)
EuropASI 0.33 34.01 b0.001
“Psychiatry”(FU) 0.22 0.002
TAS-20 at baseline 0.50 b0.001
DIF (n=148)
EuropASI 0.34 18.00 b0.001
“Alcohol” (baseline) −0.16 0.04
EuropASI
“Psychiatry”(FU) 0.29 b0.001
Age 0.21 0.007
DIF at baseline 0.44 b 0.001
DDF (n=151)
EuropASI 0.26 26.32 b0.001
“Drugs”(baseline) 0.20 0.007
DDF at baseline 0.47 b0.001
EOT (n=142)
EuropASI 0.21 18.49 b0.001
“Legal”(FU) 0.19 0.01
EOT at baseline 0.41 b0.001
Note: TAS-20 = “Toronto Alexithymia Scale”; DIF = “Difﬁculty Identifying Feelings”;
DDF = “Difﬁculty Describing Feelings”; EOT = “Externally Oriented Thinking”; FU =
follow-up.cut-off scores: a minimal change of scores near the cut-off points has
more impact than a larger change of scores with more distance from
the cut-off points. That is why we used numeric mean level scores for
the analyses between the categories.
The results showed moderate levels of relative stability, with the
lowest score for the EOT factor and the highest score for the total
TAS-20. Unlike our results, the EOT factor appeared to be the factor
with the highest relative stability in other studies (Honkalampi et
al., 2001; Rufer et al.; 2004, Saarijarvi et al., 2006; Luminet et al.,
2007; Speranza et al., 2007). The length of time between assessments
has a known negative effect on relative stability, implying that larger
changes occur as more time passes between assessments (Roberts et
al., 2006). Relative stability in our patients after 6 months was lower
than found in the general population after a period of a year
(Honkalampi et al., 2001); 18 days of detoxiﬁcation (de Timary et
al., 2008); a 14-week intervention for depression (Luminet et al.,
2001); a period of 6 months in patients with breast cancer (Luminet
et al., 2007); 70-day or 6-year follow-up of multimodal cognitive be-
haviour therapy for obsessive–compulsive patients (Rufer et al.,
2004; Rufer et al., 2006); 4–12 weeks of inpatient psychotherapy
(Stingl et al., 2008). In a 5-year follow-up study of outpatients with
major depression relative stability was lower, but not for the DDF
and EOT factor (Saarijarvi et al., 2006) and in a 3-year prospective
study in patients with eating disorders (Speranza et al., 2007), rela-
tive stability, except for the EOT factor, had nearly the same magni-
tude. The differences in time are not, conforming to the prediction
of Roberts et al. (2006), in a uniform way related to the degree of rela-
tive stability. However, the difference in populations hampers makingMultivariate linear regression analysis predicting TAS-20 “change” (baseline - follow-
up) total and factor scores from EuropASI “change” scores (baseline–follow-up), gen-
der, age, time in treatment, type of intervention and degree of alexithymia (low, mod-
erate or high) at baseline. Non-signiﬁcant variables were removed until R-squared
changed by more than 10%.
Factors β p R² F change p
Total TAS-20 (n=139)
EuropASI “change” 0.24 14.36 b0.001
“Psychiatry” 0.21 0.007
Low vs. moderate alexithymia 0.25 0.005
Low vs. high alexithymia 0.48 b0.001
DIF (n=143)
EuropASI “change” 0.19 8.11 b0.001
“Psychiatry” 0.18 0.002
Age −0.15 0.06
Low vs. moderate alexithymia 0.20 0.02
Low vs. high alexithymia 0.38 b0.001
DDF (n=145)
EuropASI “change” 0.16 6.74 b0.001
“Drugs” −0.17 0.04
“Psychiatry” 0.13 0.11
Low vs. moderate alexithymia 0.31 0.001
Low vs. high alexithymia 0.40 b0.001
EOT (n=141)
EuropASI “change” 0.10 4.79 0.003
“Psychiatry” 0.14 0.10
Low vs. moderate alexithymia 0.07 0.50
Low vs. high alexithymia 0.28 0.004
Note: TAS-20 = “Toronto Alexithymia Scale”; DIF = “Difﬁculty Identifying Feelings”;
DDF = “Difﬁculty Describing Feelings”; EOT = “Externally Oriented Thinking”.
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the variety of interventions could have different impacts on the change
in alexithymia (factors) and therefore also in their relative stability.
The differences in relative stability for baseline “low”, “moderate”
and “high” alexithymic patients has to our knowledge not been de-
scribed before. “Low” and “high” alexithymics showed low tomoderate
correlations and “moderate” alexithymics non-signiﬁcantly low corre-
lations, except for the EOT factor. In spite of demonstrating the lowest
ICC for the total sample, the EOT factor had the highest ICCs on cat-
egorical level in comparison with the total TAS and the two other fac-
tors. These ﬁndings plead against the alexithymia concept of a stable
personality construct in this population.
The regression analyses showed that alexithymia at baseline was
the best predictor of alexithymia at follow-up for total TAS-20 and
factor scores, but explained at best a moderate part of the variance.
Other variables, like age, the EuropASI domains “alcohol”, “drugs”,
“legal” and even “psychiatry”, contributed only minimally as predic-
tors. In predicting alexithymia “change scores”, changes in depression
and anxiety, as measured with the EuropASI “psychiatry” domain,
explained a minor part. When looking at change in alexithymia
scores, a larger part of the change in alexithymia was explained by
the baseline degree of alexithymia. Intervention-related variables
such as time in treatment or intervention type had no relation at all
with the change of alexithymia scores.
In response to our questions and hypotheses, we found a mean
level reduction of alexithymia and factor scores, however only for a
small part related to a reduction in anxiety and/or depression, as mea-
sured with the EuropASI “psychiatry” domain. There were signiﬁcant
differences in change of alexithymia scores between baseline “low”,
“moderate” and “high” alexithymic patients, even when controlled for
anxiety and depression. Relative stability for total TAS-20 and factor
scores was moderate to high, but predominantly lower than described
in previous research. However, relative stability showed remarkable
differences for baseline “low”, “moderate” and “high” alexithymic pa-
tients. In spite of a mean level reduction of alexithymia, for the greater
part not related to anxiety and/or depression,we did not ﬁnd a relation-
ship with type of intervention. So we have insufﬁcient arguments to at-
tribute the difference in CBT interventions to the reductions in
alexithymia.
In their meta-analysis Roberts et al. (2006) demonstrated that
personality traits do not stop changing and their ﬁndings were most
consistent with interactional models of personality development.
The interpretation of to what degree modiﬁcations of personality
represent intrinsic maturation processes or reﬂect life experiences,
perhaps facilitated by therapy or periods of abstinence, is currently
under debate (Wilberg et al., 2009). Especially for SUD patients with
a predominantly devastating lifestyle, it is conceivable that a 3-
month inpatient therapy could be a catch-up period for normative
change of personality traits. This process could be different for the in-
dividual patients and therefore be an explanation for the lower rela-
tive stability in comparison with other studies, where the
treatments were perhaps less intensive or the variety in “normative
change” possibilities between the patients was more limited. However,
that does not explain the differences we found in stability between
“low”, “moderate” and “high” alexithymic SUD patients. Alexithymia
could therefore in our patients partially be described as a state phenom-
enon, given the relation of the absolute stability of the TAS-20 with the
changes in EuropASI scores. However, the combination of the change in
absolute stability not related to anxiety or depression, the differences in
absolute stability between low,moderate and high alexithymic patients
and especially the big differences of the relative stability between these
three groups plead against alexithymia, measuredwith the TAS-20, as a
stable autonomous personality trait in this population.
In future studies, especially in intervention studies, it would be inter-
esting to compare the change of the alexithymia trait component with
the change of other personality constructs, like the ﬁve-factor model. Ifchanges in relative stability for alexithymia and these ﬁve factors are re-
lated, then that would be an argument for alexithymia as a stable per-
sonality trait. Because the differences between the low, moderate and
high alexithymic patients in absolute and relative stability have not
been reported in previous research, these results have to be replicated
to be sure that this is not a chance ﬁnding. It would also be advisable
to perform research on the stability concept of alexithymia with other
alexithymia assessment instruments, like the Bermond Vorst Alexithy-
mia Questionnaire, the Observer Alexithymia Scale and the Toronto
Structured Interview for Alexithymia (Haviland et al., 2001; Vorst and
Bermond, 2001; Bagby et al., 2006; Grabe et al., 2009) and in amore ho-
mogeneous, such a population dependent only on alcohol.
Limitations of our study were the absence of systematic urine or
blood samples to conﬁrm abstinence and not measuring the change
in depression and anxiety symptoms with more sensitive instru-
ments, like the Hamilton Depression Rating Scale (Hamilton, 1967)
or the BDI (Beck et al., 1961). Next it would be better to performmul-
timethod alexithymia assessments with an observer scale included as
the TAS-20 could be criticised for being a self-report scale and many
researchers have questioned whether a self-report instrument can
adequately assess alexithymia (Kooiman et al., 2002; Grabe et al.
2009). Finally, the heterogeneity in types of substance dependence
of our sample could be criticised.
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